Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

about

Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis The selective estrogen receptor modulators in breast cancer prevention.

P2860

Q35828551-533B0622-4611-4BFE-BC71-5C2269C5C768 Q38703578-A441D5C1-6C25-450A-8D0C-902EC2B30E8C

P2860

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

Item

http://www.wikidata.org/entity/Q43624639

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Breast cancer prevention for B ...... is there a role for tamoxifen?

@en

Breast cancer prevention for B ...... is there a role for tamoxifen?

@nl

type

Item

label

Breast cancer prevention for B ...... is there a role for tamoxifen?

@en

Breast cancer prevention for B ...... is there a role for tamoxifen?

@nl

prefLabel

Breast cancer prevention for B ...... is there a role for tamoxifen?

@en

Breast cancer prevention for B ...... is there a role for tamoxifen?

@nl

P1476

Breast cancer prevention for B ...... is there a role for tamoxifen?

@en

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Steroid receptors and cell cycle in normal mammary epithelium.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

P304

499-502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/FON.13.278

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kelly-Anne Phillips

Geoffrey J. Lindeman

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24754577

http://www.w3.org/2001/XMLSchema#string

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

about

P2860

P2860

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698